Integrated computational and biosensor-based strategies for the discovery of allosteric SMYD3 ligands using diperodon as a starting point

SMYD3 (SET- and MYND-domain containing protein 3) is an epigenetic enzyme with lysine methyl transferase activity and multiple protein binding partners. It is implicated in cancer development and active site inhibitors with antitumor activity have been developed. We have previously discovered that diperodon is an allosteric SMYD3 ligand and are interested in developing ligands that can interfere with non-catalytic functions of SMYD3, while avoiding conceivable draw-backs of targeting a conserved site in an enzyme with several close family members. Herein, the features of the diperodon site were explored via computational modelling and served as a basis for identifying analogues in commercial compound space, thus avoiding the need for in-house compound synthesis. Time-resolved grating coupled interferometry (GCI) biosensor analysis confirmed that two out of 21 acquired analogues interacted with SMYD3, with similar affinities as diperodon (KD ∼ 180 and 210 vs. ∼200 µM). As a second approach, fragmentation of diperodon followed by growing of fragments identified an additional 11 compounds in commercial compound space. GCI analysis confirmed that N-phenylformamide and three compounds evolved from this fragment interacted with SMYD3. These four ligands varied structurally from diperodon and had higher affinities (KD = 0.4-130 µM) and superior ligand efficiencies. However, all ligands interacted with rapid kinetics and weak affinities, indicating that the site had poor ligandability, possibly a result of its extremely flexible structure. Difficulties in protein production and the overall flexible structure of SMYD3, prevented NMR experiments and X-ray crystallography. Nevertheless, the combination of computational ligand design supported by biosensor-based analyses resulted in new allosteric ligands with minimal resources in a short time.